Search clinical trials for: Vildagliptin Placebo

Total 53572 results

Novartis Pharmaceuticals

Completed

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Spain, Poland, South Africa, Taiwan, Hong Kong, Norway, Italy, Bulgaria, Latvia, Lithuania, Germany, Turkey, Argentina, Israel, Korea, Republic of, Dominican Republic, Guatemala, Brazil, Colombia, Peru, Philippines, Russian Federation and more
Novartis Pharmaceuticals

Completed

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Type II Diabetes Mellitus | Congestive Heart Failure

Russian Federation, Singapore, Italy, Czechia, Lithuania, Germany, Guatemala, India, Denmark, Estonia, Slovakia, Romania, Latvia, Greece, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia

Diabetes Mellitus, Type 2

Switzerland, Germany
Novartis

Completed

Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy

Type 2 Diabetes Mellitus

China
Novartis Pharmaceuticals

Completed

Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Laboratorios Silanes S.A. de C.V.

Recruiting

Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure

Type 2 Diabetes

Mexico
University of Campania "Luigi Vanvitelli"

Completed

DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes

Chronic Foot Ulcers

Italy
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin

Diabetes Mellitus, Type 2

Germany, Switzerland
PegBio Co., Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)

China, Taiwan, Hong Kong
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan (STEADFAST)

Type 2 Diabetes Mellitus

Egypt, United Kingdom, Turkey, Lebanon, Russian Federation, Tunisia, Malaysia, Germany, Spain, Saudi Arabia, Denmark, Indonesia, Jordan, Kuwait, Singapore, United Arab Emirates
Novartis Pharmaceuticals

Completed

Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Novartis Pharmaceuticals

Completed

A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland
Universitaire Ziekenhuizen KU Leuven

Completed

Vildagliptin on Gastric Accommodation

Healthy
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Diabetes Mellitus, Type 2 | Renal Insufficiency

Spain, Canada, France, Germany, Australia, Costa Rica, Finland, Russian Federation, Argentina, India, Norway, Sweden
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Type 2 Diabetes Mellitus (T2DM)

Japan
Sadat City University

Recruiting

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Schizophrenia | Dyslipidemias

Egypt
Bio-innova Co., Ltd

Not yet recruiting

Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets

Healthy Subjects
Radboud University Medical Center

Completed

Vildagliptin and Endothelium-dependent Vasodilatation

Type 2 Diabetes | Endothelial Dysfunction

Netherlands
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Type 2 Diabetes Mellitus
Peking University

Unknown

Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients (VISA-T2DM)

Obesity | Diabetes Mellitus, Type 2

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany, United States
Novartis Pharmaceuticals

Completed

A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Ziv Hospital

Unknown

Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease

Israel
Novartis

Completed

Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Diabetes Mellitus, Type 2

Germany
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis

Completed

A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Novartis

Completed

Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers

Healthy

China
Novartis

Completed

Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Type 2 Diabetes Mellitus

Egypt
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%

Diabetes Mellitus, Type 2

Switzerland
International Bio service

Not yet recruiting

The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions

Healthy Volunteer
Novartis

Completed

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Thailand
Novartis Pharmaceuticals

Completed

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Type 2 Diabetes

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis

Completed

Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland
Novartis

Completed

Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Prediabetic State

United States
Novartis

Completed

Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

Type 2 Diabetes Mellitus

Germany
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Korea University Anam Hospital

Unknown

Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes

Diabetes Mellitus | Oxidative Stress

Korea, Republic of
Novartis

Completed

Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers

Healthy

China

3

Subscribe